153 related articles for article (PubMed ID: 38194884)
41. Next-generation sequencing informs diagnosis and identifies unexpected therapeutic targets in lung squamous cell carcinomas.
Sands JM; Nguyen T; Shivdasani P; Sacher AG; Cheng ML; Alden RS; Jänne PA; Kuo FC; Oxnard GR; Sholl LM
Lung Cancer; 2020 Feb; 140():35-41. PubMed ID: 31855703
[TBL] [Abstract][Full Text] [Related]
42. Attenuated isolated 3' signal: A highly challenging therapy relevant ALK FISH pattern in NSCLC.
Smuk G; Pajor G; Szuhai K; Morreau H; Kocsmár I; Kocsmár É; Pajor L; Kajtár B; Sárosi V; Lotz G; Tornóczky T
Lung Cancer; 2020 May; 143():80-85. PubMed ID: 32272316
[TBL] [Abstract][Full Text] [Related]
43. Real-world utility of next-generation sequencing for targeted gene analysis and its application to treatment in lung adenocarcinoma.
Kim JH; Yoon S; Lee DH; Jang SJ; Chun SM; Kim SW
Cancer Med; 2021 May; 10(10):3197-3204. PubMed ID: 33960703
[TBL] [Abstract][Full Text] [Related]
44. Molecular Diagnostic Assays and Clinicopathologic Implications of MET Exon 14 Skipping Mutation in Non-small-cell Lung Cancer.
Kim EK; Kim KA; Lee CY; Kim S; Chang S; Cho BC; Shim HS
Clin Lung Cancer; 2019 Jan; 20(1):e123-e132. PubMed ID: 30391211
[TBL] [Abstract][Full Text] [Related]
45. Effect of EGFR amplification on the prognosis of EGFR-mutated advanced non-small-cell lung cancer patients: a prospective observational study.
Peng D; Liang P; Zhong C; Xu P; He Y; Luo Y; Wang X; Liu A; Zeng Z
BMC Cancer; 2022 Dec; 22(1):1323. PubMed ID: 36528578
[TBL] [Abstract][Full Text] [Related]
46. The Prognosis of Advanced Non-Small Cell Lung Cancer Patients with Precision-Targeted Therapy Guided by NGS Testing or Routine Testing.
Tu T; Chen D; Jiang H; Ma J; Wang H; Chen C
Cancer Manag Res; 2023; 15():1307-1318. PubMed ID: 38027245
[TBL] [Abstract][Full Text] [Related]
47. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
[TBL] [Abstract][Full Text] [Related]
48. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
49. Supporting Biomarker-Driven Therapies in Oncology: A Genomic Testing Cost Calculator.
Stenzinger A; Cuffel B; Paracha N; Vail E; Garcia-Foncillas J; Goodman C; Lassen U; Vassal G; Sullivan SD
Oncologist; 2023 May; 28(5):e242-e253. PubMed ID: 36961477
[TBL] [Abstract][Full Text] [Related]
50. Clinical and Cost Implications of Universal Versus Locally Advanced-Stage and Advanced-Stage-Only Molecular Testing for Epidermal Growth Factor Receptor Mutations and Anaplastic Lymphoma Kinase Rearrangements in Non-Small Cell Lung Carcinoma: A Tertiary Academic Institution Experience.
Sauter JL; Butnor KJ
Arch Pathol Lab Med; 2016 Apr; 140(4):358-61. PubMed ID: 27028394
[TBL] [Abstract][Full Text] [Related]
51. Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer.
Pruis MA; Geurts-Giele WRR; von der TJH; Meijssen IC; Dinjens WNM; Aerts JGJV; Dingemans AMC; Lolkema MP; Paats MS; Dubbink HJ
Lung Cancer; 2020 Feb; 140():46-54. PubMed ID: 31862577
[TBL] [Abstract][Full Text] [Related]
52. Standardized and simplified reporting of next-generation sequencing results in advanced non-small-cell lung cancer: Practical indications from an Italian multidisciplinary group.
Malapelle U; Donne AD; Pagni F; Fraggetta F; Rocco EG; Pasello G; Perrone G; Pepe F; Vatrano S; Pignata S; Pinto C; Pruneri G; Russo A; Soto Parra HJ; Vallone S; Marchetti A; Troncone G; Novello S
Crit Rev Oncol Hematol; 2024 Jan; 193():104217. PubMed ID: 38040072
[TBL] [Abstract][Full Text] [Related]
53. Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.
Qin K; Hou H; Liang Y; Zhang X
BMC Cancer; 2020 Apr; 20(1):328. PubMed ID: 32299384
[TBL] [Abstract][Full Text] [Related]
54. Real-world adherence and persistence with anaplastic lymphoma kinase inhibitors in non-small cell lung cancer.
Ganti AK; Lin CW; Yang E; Wong WB; Ogale S
J Manag Care Spec Pharm; 2022 Mar; 28(3):305-314. PubMed ID: 34913728
[No Abstract] [Full Text] [Related]
55. Alectinib versus crizotinib in ALK-positive advanced non-small cell lung cancer and comparison of next-generation TKIs after crizotinib failure: Real-world evidence.
Wang Y; Shen S; Hu P; Geng D; Zheng R; Li X
Cancer Med; 2022 Dec; 11(23):4491-4500. PubMed ID: 35616090
[TBL] [Abstract][Full Text] [Related]
56. Comparison of real-life data from patients with NGS panel negative and
Gökyer A; Küçükarda A; Köstek O; Gökmen İ; Özcan E; Sayın S; Taştekin E; Hacıoğlu B; Erdoğan B; Uzunoğlu S; Çiçin İ
Tumori; 2022 Apr; 108(2):141-146. PubMed ID: 33624577
[TBL] [Abstract][Full Text] [Related]
57. Mutation Spectrum of
Mao L; Zhao W; Li X; Zhang S; Zhou C; Zhou D; Ou X; Xu Y; Tang Y; Ou X; Hu C; Ding X; Luo P; Yu S
Pathol Oncol Res; 2021; 27():602726. PubMed ID: 34257561
[TBL] [Abstract][Full Text] [Related]
58. Next-generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non-small cell lung cancer.
Zhang Y; Xiong L; Xie F; Zheng X; Li Y; Zhu L; Sun J
Cancer Med; 2021 Jul; 10(14):4697-4709. PubMed ID: 34173341
[TBL] [Abstract][Full Text] [Related]
59. Epidermal growth factor receptor and anaplastic lymphoma kinase testing and mutation prevalence in patients with advanced non-small cell lung cancer in Switzerland: A comprehensive evaluation of real world practices.
Ess SM; Herrmann C; Frick H; Krapf M; Cerny T; Jochum W; Früh M
Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 28557060
[TBL] [Abstract][Full Text] [Related]
60. Gene rearrangement detection by next-generation sequencing in patients with non-small cell lung carcinoma.
Brisudova A; Skarda J
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2020 Jun; 164(2):127-132. PubMed ID: 32284620
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]